NRAS and neoplasm: An inferior survival after relapse for the panitumumab treated patients was observed, especially for the population with a mutation (either KRAS, BRAF, NRAS or PIK3CA), possibly due to accelerated tumour growth caused by the anti-EGFR therapy [18].